UroGen Pharma Ltd. (NASDAQ:URGN) was founded in 2004. It is an Israeli company. It was previously headquartered in Ra’anana, Israel, and now headquartered in New York City, New York, USA, with 88 full-time employees (9/30/2019) , Is a clinical stage biopharmaceutical company focusing on the development of urological pathology therapies.
UroGen Pharma (URGN):
Candidate products of UroGen Pharma Ltd. include:
- MitoGel and VesiGel (UGN-101 and UGN-102) are chemotherapeutic generic drugs Mitomycin C preparations (a proprietary formulation of the chemotherapy drug mitomycin), currently only used as adjuvants or supplements for the treatment of urothelial cancer in aqueous preparations After treatment.
- UroGen Pharma is developing a chemical anti-inflammatory agent candidate product designed for non-surgical removal of tumors to treat various forms of non-muscular invasive urothelial cancer, including mild upper urothelial cancer and mild bladder cancer.
UroGen Pharma Ltd. has signed a license agreement with Allergan Pharmaceuticals International Limited to develop and commercialize drugs containing RTGel and Clostridial toxin.
UroGen Pharma (URGN) investment:
UroGen Pharma Ltd. (NASDAQ:URGN) went public on 5/4/2017 together with Biohaven Pharmaceutical Holding Company (BHVN) and listed on NASDAQ. The issue price was US$13. It issued 4,473,373 shares and raised US$58,153,849.00. , Stock code: URGN.